ProCE Banner Activity

DESTINY-Breast07: Trastuzumab Deruxtecan ± Pertuzumab for Previously Untreated HER2+ Metastatic Breast Cancer

Conference Coverage

Interim analysis of the phase Ib/II DESTINY-Breast07 trial showed promising antitumor activity of T-DXd monotherapy and T-DXd + pertuzumab as first-line therapy for HER2+ metastatic breast cancer, with no new safety signals.

Released: June 04, 2024

Expiration: June 03, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.


Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation